Skip to main content
Top
Published in: Acta Diabetologica 2/2018

Open Access 01-02-2018 | Original Article

The potential role of the osteopontin–osteocalcin–osteoprotegerin triad in the pathogenesis of prediabetes in humans

Authors: Giuseppe Daniele, Deidre Winnier, Andrea Mari, Jan Bruder, Marcel Fourcaudot, Zuo Pengou, Andrea Hansis-Diarte, Christopher Jenkinson, Devjit Tripathy, Franco Folli

Published in: Acta Diabetologica | Issue 2/2018

Login to get access

Abstract

Aims

To examine the relationship between hormones involved in bone remodeling and glucose metabolism alterations in prediabetes.

Methods

Individuals (n = 43) with NGT (BMI = 31.1 ± 1.1 kg/m2) and individuals (n = 79) with impaired glucose regulation (IGR) (BMI = 31.9 ± 1.2 kg/m2) including subjects with IFG, IGT, and IFG-IGT underwent OGTT and DXA. Osteopontin (OPN), osteocalcin (OCN), osteoprotegerin (OPG), and PTH levels were measured at fasting. Beta-cell function was calculated using C-peptide deconvolution. Dynamic indexes of insulin sensitivity were calculated from OGTT. A subgroup underwent to a euglycemic hyperinsulinemic clamp with 3-3H-glucose to estimate the endogenous glucose production (EGP) and insulin-mediated body glucose disposal (TGD/SSPI).

Results

OPN was higher in IGR compared to NGT (5.3 ± 0.5 vs. 3.3 ± 0.2 μg/mL; p = 0.008) and in isolated IGT compared to IFG and IFG-IGT (6.3 ± 0.5 vs. 4.5 ± 0.3 and 5.4 ± 0.5 μg/mL; p = 0.02). OCN was similar in IFG and NGT but lower in IGT and IFG-IGT compared to NGT (7.2 ± 0.3 and 5.4 ± 0.2 vs. 8.3 ± 0.3 ng/mL; p < 0.01). OPN was positively correlated with HbA1c, fasting and 2 h plasma glucose and PTH. OCN was negatively correlated with body fat, 2 h plasma glucose, insulin and positively correlated with Stumvoll index. OPG correlated with TGD/SSPI (r = − 0.29; p < 0.05), EGP, and hepatic insulin resistance index in IGR (r = 0.51, r = 0.43; p < 0.01). There was no correlation between PTH and insulin sensitivity or Beta-cell function parameters.

Conclusions

In prediabetes, hormones known to be involved in bone remodeling may affect glucose metabolism before overt T2DM occurs with tissue-specific mechanisms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Daniele G, Abdul-Ghani M, DeFronzo RA (2014) What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 15:2003–2018CrossRefPubMed Daniele G, Abdul-Ghani M, DeFronzo RA (2014) What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 15:2003–2018CrossRefPubMed
2.
go back to reference Federici M, Hribal M, Perego L et al (2001) High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50:1290–1301CrossRefPubMed Federici M, Hribal M, Perego L et al (2001) High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50:1290–1301CrossRefPubMed
3.
go back to reference Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169–2181CrossRefPubMedPubMedCentral Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169–2181CrossRefPubMedPubMedCentral
4.
go back to reference Folli F, Okada T, Perego C et al (2011) Altered insulin receptor signalling and beta-cell cycle dynamics in type 2 diabetes mellitus. PLoS ONE 6:e28050CrossRefPubMedPubMedCentral Folli F, Okada T, Perego C et al (2011) Altered insulin receptor signalling and beta-cell cycle dynamics in type 2 diabetes mellitus. PLoS ONE 6:e28050CrossRefPubMedPubMedCentral
5.
go back to reference Daniele G, Guardado Mendoza R, Winnier D et al (2014) The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131CrossRefPubMed Daniele G, Guardado Mendoza R, Winnier D et al (2014) The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131CrossRefPubMed
6.
go back to reference Guardado Mendoza R, Perego C, Finzi G et al (2015) Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas). Diabetologia 58:1814–1826CrossRefPubMedPubMedCentral Guardado Mendoza R, Perego C, Finzi G et al (2015) Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas). Diabetologia 58:1814–1826CrossRefPubMedPubMedCentral
7.
go back to reference Schroeder EB, Chambless LE, Liao D et al (2005) Atherosclerosis risk in communities s: diabetes, glucose, insulin, and heart rate variability: the atherosclerosis risk in communities (ARIC) study. Diabetes Care 28:668–674CrossRefPubMed Schroeder EB, Chambless LE, Liao D et al (2005) Atherosclerosis risk in communities s: diabetes, glucose, insulin, and heart rate variability: the atherosclerosis risk in communities (ARIC) study. Diabetes Care 28:668–674CrossRefPubMed
8.
go back to reference Plantinga LC, Crews DC, Coresh J et al (2010) Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 5:673–682CrossRefPubMedPubMedCentral Plantinga LC, Crews DC, Coresh J et al (2010) Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 5:673–682CrossRefPubMedPubMedCentral
9.
go back to reference Tesfaye S, Boulton AJ, Dyck PJ et al (2010) Toronto diabetic neuropathy expert G: diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33:2285–2293CrossRefPubMedPubMedCentral Tesfaye S, Boulton AJ, Dyck PJ et al (2010) Toronto diabetic neuropathy expert G: diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33:2285–2293CrossRefPubMedPubMedCentral
10.
go back to reference Wei J, Ferron M, Clarke CJ et al (2014) Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Investig 124:1–13CrossRefPubMed Wei J, Ferron M, Clarke CJ et al (2014) Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Investig 124:1–13CrossRefPubMed
11.
go back to reference Daniele G, Winnier D, Mari A et al (2015) Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism. Diabetes Care 38:1509–1517CrossRefPubMed Daniele G, Winnier D, Mari A et al (2015) Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism. Diabetes Care 38:1509–1517CrossRefPubMed
13.
go back to reference Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270CrossRefPubMedPubMedCentral Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270CrossRefPubMedPubMedCentral
14.
15.
go back to reference Hofbauer LC, Heufelder AE (2000) Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355–2363PubMed Hofbauer LC, Heufelder AE (2000) Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355–2363PubMed
16.
go back to reference Jansson AM, Hartford M, Omland T et al (2012) Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes. Arterioscler Thromb Vasc Biol 32:3041–3049CrossRefPubMed Jansson AM, Hartford M, Omland T et al (2012) Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes. Arterioscler Thromb Vasc Biol 32:3041–3049CrossRefPubMed
17.
go back to reference DeFronzo RA, Ferrannini E, Groop L et al (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019CrossRefPubMed DeFronzo RA, Ferrannini E, Groop L et al (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019CrossRefPubMed
18.
go back to reference Roy B, Curtis ME, Fears LS, Nahashon SN, Fentress HM (2016) Molecular mechanisms of obesity-induced osteoporosis and muscle atrophy. Front Physiol 7:439CrossRefPubMedPubMedCentral Roy B, Curtis ME, Fears LS, Nahashon SN, Fentress HM (2016) Molecular mechanisms of obesity-induced osteoporosis and muscle atrophy. Front Physiol 7:439CrossRefPubMedPubMedCentral
19.
go back to reference Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377CrossRefPubMed Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377CrossRefPubMed
20.
go back to reference Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166CrossRefPubMed Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166CrossRefPubMed
21.
go back to reference Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420–430CrossRefPubMed Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420–430CrossRefPubMed
22.
go back to reference Barchetta I, Alessandri C, Bertoccini L et al. (2015) Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. Eur J Endocrinol/European Federation of Endocrine Societies Barchetta I, Alessandri C, Bertoccini L et al. (2015) Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. Eur J Endocrinol/European Federation of Endocrine Societies
23.
go back to reference Berezin AE, Kremzer AA (2013) Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 229:475–481CrossRefPubMed Berezin AE, Kremzer AA (2013) Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 229:475–481CrossRefPubMed
24.
go back to reference Saleem U, Mosley TH Jr, Kullo IJ (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 30:1474–1478CrossRefPubMedPubMedCentral Saleem U, Mosley TH Jr, Kullo IJ (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 30:1474–1478CrossRefPubMedPubMedCentral
25.
go back to reference Mera P, Laue K, Ferron M et al (2016) Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab 23:1078–1092CrossRefPubMedPubMedCentral Mera P, Laue K, Ferron M et al (2016) Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab 23:1078–1092CrossRefPubMedPubMedCentral
26.
go back to reference Stern JH, Rutkowski JM, Scherer PE (2016) Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab 23:770–784CrossRefPubMedPubMedCentral Stern JH, Rutkowski JM, Scherer PE (2016) Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab 23:770–784CrossRefPubMedPubMedCentral
27.
go back to reference O’Neill HM, Lally JS, Galic S et al (2014) AMPK phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation and insulin sensitivity in mice. Diabetologia 57:1693–1702CrossRefPubMed O’Neill HM, Lally JS, Galic S et al (2014) AMPK phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation and insulin sensitivity in mice. Diabetologia 57:1693–1702CrossRefPubMed
28.
go back to reference Kumashiro N, Erion DM, Zhang D et al (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 108:16381–16385CrossRefPubMedPubMedCentral Kumashiro N, Erion DM, Zhang D et al (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 108:16381–16385CrossRefPubMedPubMedCentral
29.
go back to reference Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29:939–960CrossRefPubMed Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29:939–960CrossRefPubMed
30.
go back to reference Monseu M, Dubois S, Boursier J et al (2016) Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. Diabetes Metab 42:364–367CrossRefPubMed Monseu M, Dubois S, Boursier J et al (2016) Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. Diabetes Metab 42:364–367CrossRefPubMed
33.
go back to reference Akmal M, Massry SG, Goldstein DA, Fanti P, Weisz A, DeFronzo RA (1985) Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Investig 75:1037–1044CrossRefPubMedPubMedCentral Akmal M, Massry SG, Goldstein DA, Fanti P, Weisz A, DeFronzo RA (1985) Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Investig 75:1037–1044CrossRefPubMedPubMedCentral
34.
go back to reference Muscogiuri G, Sorice GP, Prioletta A et al (2010) 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring) 18(10):1906–1910CrossRef Muscogiuri G, Sorice GP, Prioletta A et al (2010) 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring) 18(10):1906–1910CrossRef
35.
go back to reference Gulseth HL, Wium C, Angel K, Eriksen EF, Birkeland KI (2017) Effects of vitamin D supplementation on insulin sensitivity and insulin secretion in subjects with type 2 diabetes and vitamin d deficiency: a randomized controlled trial. Diabetes Care 40(7):872–878CrossRefPubMed Gulseth HL, Wium C, Angel K, Eriksen EF, Birkeland KI (2017) Effects of vitamin D supplementation on insulin sensitivity and insulin secretion in subjects with type 2 diabetes and vitamin d deficiency: a randomized controlled trial. Diabetes Care 40(7):872–878CrossRefPubMed
36.
go back to reference Garbossa GS, Folli F (2017) Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism. Rev Endocr Metab Disord 18(2):243–258CrossRefPubMed Garbossa GS, Folli F (2017) Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism. Rev Endocr Metab Disord 18(2):243–258CrossRefPubMed
37.
go back to reference Clarys JP, Martin AD, Marfell-Jones MJ, Janssens V, Caboor D, Drinkwater DT (1999) Human body composition: a review of adult dissection data. Am J Hum Biol 11:167–174CrossRefPubMed Clarys JP, Martin AD, Marfell-Jones MJ, Janssens V, Caboor D, Drinkwater DT (1999) Human body composition: a review of adult dissection data. Am J Hum Biol 11:167–174CrossRefPubMed
38.
go back to reference Zihlman AL, Bolter DR (2015) Body composition in Pan paniscus compared with Homo sapiens has implications for changes during human evolution. Proc Natl Acad Sci USA 112:7466–7471CrossRefPubMedPubMedCentral Zihlman AL, Bolter DR (2015) Body composition in Pan paniscus compared with Homo sapiens has implications for changes during human evolution. Proc Natl Acad Sci USA 112:7466–7471CrossRefPubMedPubMedCentral
39.
go back to reference Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R et al (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97:234–241CrossRefPubMed Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R et al (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97:234–241CrossRefPubMed
41.
go back to reference Yu OH, Richards B, Berger C et al (2017) The association between sclerostin and incident type 2 diabetes risk: a cohort study. Clin Endocrinol 86:520–525CrossRef Yu OH, Richards B, Berger C et al (2017) The association between sclerostin and incident type 2 diabetes risk: a cohort study. Clin Endocrinol 86:520–525CrossRef
Metadata
Title
The potential role of the osteopontin–osteocalcin–osteoprotegerin triad in the pathogenesis of prediabetes in humans
Authors
Giuseppe Daniele
Deidre Winnier
Andrea Mari
Jan Bruder
Marcel Fourcaudot
Zuo Pengou
Andrea Hansis-Diarte
Christopher Jenkinson
Devjit Tripathy
Franco Folli
Publication date
01-02-2018
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-017-1065-z

Other articles of this Issue 2/2018

Acta Diabetologica 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.